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Abstract
Background: Different neurological disorders frequently display antibodies against several self-glycans. Increasing
evidence supports their pathogenic role; however, far less is known about their origin. Meanwhile, antibodies
recognizing non-self glycans appear in normal human serum during immune response to bacteria.
Methods: Using high performance thin layer chromatography-immunostaining, we comparatively evaluated
humoral immune response (IgG and IgM immunoreactivity) against glycolipids carrying self-glycans (GM3/GM2/
GM1/GD1a/GD1b/GD3/GT1b/GQ1b) and non-self glycans (Forssman/GA1/“A” blood group/Nt7) in sera from 383
patients with neurological disorders along with 87 healthy controls.
Results: In contrast to no healthy controls having anti-self glycan IgG antibodies, one-fifth of patients’ sera had
anti-self glycan IgG antibodies: remarkably, 60% of these occurred without IgM antibodies of the same specificity.
Contrary to this unusual fact (anti-self glycan IgG occurrence without simultaneous presence of IgM having the
same specificity ~ IgG/IgM discordance), all IgG antibodies against non-self glycans occurred simultaneously with
their IgM antibody counterpart (i.e. 0% discordance). When analyzed closer, the IgG/IgM discordance frequency for
anti-self glycans exhibited a dual trend: below 40% for IgG antibodies against GM2, GM1 and GD1b, and greater
than 53% for IgG antibodies against the remaining self glycans. Interestingly, this discordance behavior was
common to several different neurological disorders.
Conclusions: Classic immunology principles indicate this anti-self glycan IgG/IgM discordance should not occur in
an antibody response; its unusual presence is discussed within the “binding site drift hypothesis” context, where
anti-self glycan IgG antibodies could originate from pre-existing IgG recognizing structurally-related non-self
glycans.
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Background
Glycolipids are plasma membrane lipids displaying gly-
cans as their hydrophilic head groups, which are access-
ible to binding by viruses, toxins and antibodies [1].
Anti-glycan antibodies are antibodies that, regardless of
the immunogen that induces them, recognize saccharide
sequences in one or more types of glycoconjugates [2].
Naturally occurring anti-glycan antibodies recognizing
non-self carbohydrate sequences are routinely detected
in normal subjects [3]. Typical examples are the ABO
blood group agglutinins – i.e. sera from individuals of
the blood group “0” contain antibodies that agglutinate
blood group “A”/“B” red blood cells [4]. Since pioneering
work of Springer [5] it is widely accepted that these anti-
bodies are part of the normal immune response to bac-
teria colonizing respiratory or intestinal tract. A similar
origin is described for IgM antibodies against a few self
glycan-carrying glycolipids such as gangliosides GM1
and GD1b [6], although these normal antibodies are of
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low affinity and non-pathogenic [7]. In despite of this,
immune reactivity recognizing self-glycolipids is often
associated with autoimmune diseases [8]. In particular, a
variety of neurological diseases present antibodies that
recognize gangliosides (glycolipids abundantly found in
nervous system) [9]. Unlike the large body of data indi-
cating anti-ganglioside antibodies are responsible for
triggering nervous system dysfunction through multiple
mechanisms [10], much less is known about their origin.
Infection of specific serotypes of Campylobacter jejuni
cause Guillain-Barré syndrome associated with the pres-
ence of anti-GM1 antibodies [11]. These serotypes con-
tain lipooligosaccharides carrying GM1-glycan (terminal
tetrasaccharide) that can induce production of anti-gly-
can IgG-antibodies recognizing ganglioside GM1 (“mo-
lecular mimicry” hypothesis) [12]. Still, only a small
minority of individuals infected with proper C. jejuni se-
rotypes develops further neuropathy [13, 14], suggesting
requirement for a “host susceptibility factor” that has
not yet been identified [15]. On the other hand, it has
been proposed that chronic neuropathy-associated anti-
GM1 antibodies of the IgM isotype could originate by
changes in the binding site of their normal counterpart
(“binding site drift” hypothesis) [16]. “Binding site drift”
can explain the “host susceptibility factor” of “molecular
mimicry” hypothesis; therefore, both hypotheses can be
regarded as complementary to explain the origin of anti-
GM1 antibodies in disease [2]. Nevertheless, little is
known about the origin of several other anti-self glyco-
lipid antibodies associated to neurological diseases, espe-
cially for those having no “normal” IgM-antibodies [7].
In the present work, we comparatively evaluated the
humoral immune response against various self and non-
self glycan-carrying glycolipids in sera from patients with
neurological disorders. We found remarkable differences
between both antibody responses that were analyzed in
the context of the “binding site drift” hypothesis, aiming




Serum samples were obtained from 383 patients with
early symptoms of neurological disorders: amyotrophic
lateral sclerosis, n = 76; Guillain-Barré syndrome, n = 75;
asymmetric motor neuropathy, n = 38; chronic inflam-
matory demyelinating polyneuropathy, n = 36; sensory
neuropathy, n = 31; multifocal motor neuropathy, n = 25;
sensory motor neuropathy, n = 23; Miller Fisher syn-
drome, n = 19; lower motor neuron disease, n = 18;
mononeuropathy, n = 9; cranial neuropathy, n = 8; para-
neoplastic syndrome, n = 6; multiple sclerosis, n = 4; dia-
betic neuropathy, n = 4; neuropathy with monoclonal
gammopathy, n = 4; myasthenia gravis, n = 3; hereditary
neuropathy, n = 2; amyotrophic neuralgia, n = 1; lumbo-
sacral radiculitis, n = 1. These patients attended Neur-
ology services from Hospital “Ramos Mejía” and
Hospital Nacional de Clínicas “José de San Martín”, Bue-
nos Aires, Argentina. Blood was collected before the pa-
tient underwent any immune treatment. After clot
separation, sera were frozen and submitted to our la-
boratory for routine determination of anti-glycolipid
antibodies. Normal human serum samples (n = 87) from
healthy adult volunteers with negative serology for com-
mon infectious diseases were provided by Blood Bank of
the University of Córdoba, Argentina. All procedures,
performed in accordance with Ethical Guidelines on Re-
search Involving Human Subjects [17] and with ethical
standards as laid down in the 1964 Declaration of
Helsinki and its later amendments, were approved by
the Ethics Committee of CIQUIBIC-CONICET; in-
formed consent was obtained from the patients.
Glycolipids
The following biological materials were used as source of
glycolipids: human brain for GM1, GD1a, GD1b, GT1b,
and GQ1b; Sandhoff disease human brain for GM2; dog
erythrocytes for GM3; chick brain for GD3; sheep erythro-
cytes for Forssman glycolipid (Forssman); human blood
group “A” meconium for blood group “A” glycolipid; Cal-
liphora vicina pupae for Nt7 glycolipid [18]. Folch upper
phase of lipid extract [19] was purified by DEAE -chroma-
tography [20] and HPLC on Iatrobeads silica-gel column
[21]. Asialo-GM1 (GA1) was prepared by acid hydrolysis
of cow brain gangliosides [22].
High performance thin layer chromatography (HPTLC)-
immunostaining
HPTLC with subsequent immunodetection (HPTLC-I)
is considered the “golden standard” to detect anti-glyco-
lipid antibodies and confirm autoreactivity results [23,
24]. Glycolipids (0.3 nmoles each) were separated on
HPTLC plates (Merck) in the running solvent chloro-
form-methanol-aqueous 0.2% CaCl2 (45:45:10), using a
tank designed to obtain highly reproducible chromato-
grams [25]. After air-drying, the plates were coated by
dipping for 2 min in a 0.5% solution of poly (isobutyl-
methacrylate) (Aldrich Chemical Co., Milwaukee, WI,
USA) in n-hexane-chloroform (9:1). Plates were blocked
with BSA-PBSt (1% bovine serum albumin in phosphate
buffered saline containing 0.05% Tween 20) for 1 h, in-
cubated overnight with BSA-PBSt diluted serum, and
washed thoroughly with PBSt. Binding was detected fol-
lowing 2 h incubation with BSA-PBSt diluted (1/1000)
peroxidase-conjugated anti-human IgM (μ chain) or IgG
(γ chain) goat antibodies (Sigma, USA). All the incuba-
tion steps were performed at 4 °C. After washing, color
development was achieved in a substrate solution
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containing 2.8 mM 4-chloro-1-naphtol and 0.01% H2O2
in methanol-20 mM Tris-HCl buffer, pH 7.4 (1:29). The
reaction was stopped after 20 min by washing the plates
with PBSt. For usual immunostaining assay, sera were
used at 1/20 dilutions. The presence of distinguishable
immunostaining spot at these dilutions was considered a
positive reactivity. In cases were only IgG was detected,
higher serum dilutions were used (1/50, 1/500) to avoid
potential IgM binding inhibition due to an IgG excess.
To ensure data objectiveness, immunostaining results
collected by first author (RDL) were checked against a
blind assessment performed by one of the remaining au-
thors (GAN).
Statistical analyses
Antibody results were informed as categorical data and
combined into groups for statistical purposes. Immuno-
staining against non-self glycans (GA1, Forssman, Nt7
and blood group “A” glycolipid for “0” and “B” blood
group individuals) was grouped as “non-self glycan”
reactivity. Since IgM populations against GM1, GD1b and
GM2 have been described in normal human sera [7], re-
activity against these glycolipids was considered a sub-
group (“self glycan A”) within anti-self glycan antibody
populations. Finally, response against GM3, GD3, GD1a,
GT1b and GQ1b was counted as another subgroup (“self
glycan B”). Data were examined by Chi-square or Fisher’s
exact test with Prism 6 (GraphPad software, La Jolla, CA).
Differences with P value < 0.05 were considered
significant.
Results
Previous reports have described the presence of anti-
ganglioside antibodies in diverse diseases [26–33]. In a
general screening searching for anti-glycolipid antibodies
in neurological disorders, we analyzed serum samples
from 383 patients, along with sera from 87 healthy con-
trols. Using HPTLC immunostaining, we evaluated in
both groups of samples the IgM and IgG antibody re-
activity against self-glycan-carrying glycolipids: GM3,
Fig. 1 Reactivity of IgM- and IgG-antibodies against glycolipid self and non-self glycans. Representative results of the anti-non-self glycan and
anti-self glycan immunoreactivity in (a) normal human sera and in (b) neurological disorder patients. On the left are glycolipids visualized using
orcinol reagent
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GM2, GM1, GD3, GD1a, GD1b, GT1b and GQ1b. For
the immunostaining assay we used relatively low (1/20)
serum dilutions, that allow detection of antibodies oc-
curring at low titer. With variable immunostaining in-
tensity, 75 patients (19.6%) were clearly positive for
antibodies of the IgG isotype for at least one self-glycan
antigen, while control sera were negative (Fig. 1). Some
patients had IgG antibodies against two or more “self
glycans”. Although similar percentages of antibody posi-
tive-patients have been published by several laboratories
[26, 30, 34]), we observed a remarkable behavior of the
antibody response: most of the IgG-reactivity against self
glycans occurred without their IgM counterpart. De-
pending of the antibody specificity, the IgG/IgM discord-
ance (IgG occurrence without simultaneous presence of
IgM having the same specificity) ranged from 33% for
those recognizing GM2 to 100% for antibodies recogniz-
ing GT1b (Figs. 2 and 3). Importantly, IgG/IgM discord-
ance for the “self glycan A” subgroup (GM1, GD1b and
GM2: all three reported to present IgM populations in
normal human sera [7]) was significantly lower than that
for the “self glycan B” subgroup (p < 0.0001; see Fig. 3,
Additional file 1 and “Methods”).
The trend of IgG/IgM discordance for reactivity against
self glycans was consistently observed across the different
patient subpopulations, regardless of their diagnoses: eval-
uations within each patient subpopulation showed IgG/
IgM discordances were always higher for the “self glycan
B” subgroup. Statistical evaluation comparing discordance
data between patient subpopulations having 20 or more
individuals indicated the discordance magnitude was com-
parable throughout them (i.e. no significant differences;
see Fig. 3). When compared individually within each pa-
tient subpopulation the discordance differences were mar-
ginally significant or not significant.
To assess if the observed IgG/IgM discordance was
specific for anti-self glycan immune responses, we stud-
ied antibody reactivity to glycolipids bearing non-self
glycans: Forssman, GA1, Nt7, and “A” blood group gly-
colipid, where the last one was considered non-self gly-
can for “0” and “B” blood group individuals (“A”
individuals do not present anti-“A” antibodies). None of
the patients exhibited IgG antibodies without their IgM
counterpart, for any of the assayed non-self glycans
(Figs. 1 and 2). As expected, the absence of IgG/IgM dis-
cordance for non-self glycans was significantly different
compared to those from any of the anti-self glycan re-
activity subgroups (p < 0.0001).
Examining co-occurrences of IgG populations against
the different self glycans indicated a predominance (53
out of 75 patients, ~ 71%) of single self-glycan antigen
reactivity (Additional file 2: Figure S1). Within the
remaining 29% (22 patients), some isolated co-occur-
rences in antibody reactivity were observed for certain
structures like GM1/GD1b (sharing terminal Galβ1-
3GalNAc) or GD1b/GD3/GQ1b (b-series gangliosides),
although no predominant events were detected (Add-
itional file 2: Figure S1). Finally, regarding comparisons
between GA1 and GM1 (structurally-related glycans),
we found simultaneous occurrence with anti-GA1 IgG
in 9 of 26 (34%) samples positive for anti-GM1 IgG
antibodies.
For some randomly selected discordant serum sam-
ples, whole IgG fraction was removed using protein G-
affinity columns. The non-adsorbed fraction (containing
serum IgM-antibodies) had no anti-self glycan IgM re-
activity (see examples in Additional file 3: Figure S2).
These results indicate that absence of IgM reactivity in
IgG-reactive sera is not due to IgG interference (antigen
competition or anti-idiotype antibodies).
Discussion
Humoral immune responses are complex and lead to dif-
ferent effector functions depending on their nature [35].
Glycan antigens have become important antibody targets
in several medical contexts, such as vaccine design, diag-
nostic assays, and antibody-based therapies [36–38]. Im-
mune response to non-self glycans is one of the early
events in the defense against bacteria [39]. Natural infec-
tion of the gastrointestinal and respiratory tracts of the
human body by pathogenic and non-pathogenic bacteria
stimulate the immune system. Consequently, soon after
birth, antibodies recognizing a variety of bacterial glycans
are detected in children sera [6, 40, 41]. On the other
hand, self-glycans carried by glycolipids have been associ-
ated to autoimmune diseases [9, 42]. The structural simi-
larity of self and non-self glycans suggested both immune
responses could be related [2]. In the present work, we
characterized the antibody immune response against gly-
colipids carrying diverse self glycans in a large cohort of
patients with neurological disorders, along with healthy
controls. Antibodies of the IgG isotype recognizing self
glycans were only detected in patient sera, with two types
of results: some IgG-antibodies occurred with IgM of the
same specificity, but most of them were discordant (i.e.
without their IgM counterpart). To know if this discord-
ance was exclusive of an autoimmune response, antibodies
recognizing non-self glycan were studied in some discord-
ant patient sera: in all cases where IgG reactivity was
found, IgM of the same specificity was also present
(Fig. 2), thus giving a relevant context to the IgG/IgM
antibody discordance for anti-self glycan antibodies.
Even though numerous studies and case reports in the lit-
erature have already portrayed antibodies of the IgG iso-
type against self glycan glycolipids in Guillain-Barré
syndrome and related disorders, often they either provided
information only for one or few glycolipids at the time (e.g.
[27, 30]), used ELISA (instead of HPTLC-immunostaining)
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Fig. 2 (See legend on next page.)
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Fig. 2 IgG/IgM discordance of IgG antibodies against diverse non-self and self glycan-carrying glycolipids analyzed in this study. Percentage of
IgG/IgM discordance (percentage of samples having IgG antibodies with IgM antibodies of the same specificity) in patients with neurological
disorders (positive for anti-self glycans and for anti-non-self glycans IgG antibodies of defined specificity). Oligosaccharide sequence of each
glycosphingolipid recognized by antibodies is displayed. IgG/IgM discordance comparisons between “non-self glycan-”, “self glycan A” and “self
glycan B” reactivities (these latter divided by a dashed line, see Methods) were all statistically significant (p < 0.0001, Fisher’s exact test). Anti-GA1
antibodies were measured in all patient samples, whereas the remaining anti-non self glycan antibodies were evaluated in a randomly selected
fraction of patient sera (n = 30) that were positive for anti-self glycan IgG antibodies
Fig. 3 Distribution of anti-self glycan glycolipid and anti-GA1 antibodies in the different subpopulations of neurological disorder patients. Within
each pie chart, the number of patients presenting antibody reactivity of the IgM (“IgM only”, blue), IgG (“IgG only”, red) or both isotypes (“IgM &
IgG”, green) against the different self glycan glycolipids is displayed for each patient subpopulation and for all patients combined. The fraction of
pie chart depicting “IgG only” reactivity represents the percentage of IgG/IgM discordance. Similar information is presented for anti-GA1
antibodies (non-self glycan glycolipid). “Self glycan A” subgroup comprises antibodies against GM1, GD1b and GM2, for which IgM reactivity
populations have been characterized in normal human sera. “Self glycan B” subgroup includes antibody reactivity detecting the remaining
glycolipids (GM3, GD3, GD1a, GT1b and GQ1b). “Sub-total A” plots sum the data for all “self glycan A” subgroup antibodies, while “sub-total B”
column does it for all “self glycan B” subgroup antibodies. Far right column (“Total”) combines the data for all the anti-self glycan glycolipid
antibodies. Total IgG/IgM discordance comparisons between each subpopulation of neurological disorder patients were statistically not
significant. Comparisons of “sub-total A” versus “sub-total B” IgG/IgM discordance within each subpopulation of neurological disorder were not
significant, whereas for “All patients” data combined, the comparison was statistically meaningful (Fisher’s exact test; ****, p < 0.0001). ALS,
amyotrophic lateral sclerosis; GBS, Guillain-Barré syndrome; AMN, asymmetric motor neuropathy; CIDP, chronic inflammatory demyelinating
polyneuropathy; SN, sensory neuropathy; MMN, multifocal motor neuropathy; SMN, sensory motor neuropathy; MFS, Miller Fisher syndrome;
LMND, lower motor neuron disease; MN, mononeuropathy; Other, other neuropathies (see Methods and Additional file 1 for full details)
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at higher serum dilutions than ours (e.g. [43, 44]) or,
ultimately, did not include reactivity detection for glyco-
lipids carrying closely-related, heteroantigenic glycans (e.g.
[45, 46]). From a thorough revision of the literature we can
say this discordance finding has not been remarked nor
discussed before.
According to classical immunology principles, B-lym-
phocytes can be stimulated directly to produce IgM anti-
bodies, whereas IgG production involves additional
immune processes including T-cell cooperation. Thus,
IgG antibody production should be accompanied by IgM
antibodies and the IgG/IgM discordance would not
occur. Since the IgG/IgM discordance was observed only
in the antibody response directed to self glycans, its oc-
currence should be explained in the context of an auto-
immune response. The occurrence of this antibody
discordance does not seem to be related with a specific
type of neurological disorder, since it was observed with
similar magnitude in the different diseases evaluated.
Previous work from our group showed that variations in
antibody populations recognizing self-glycan glycolipids
GM1 and GD1b are irrespective of motor neuropathy
variants [47]. Some of these variations can even present
certain heterogeneity among different patients suffering
the same neuropathy [48, 49]. Each nerve of the periph-
eral nervous system has a specific function, and the ex-
perienced symptom/s in a neurological disease are
determined by the type of nerve/s affected. There are
various other factors that influence a neurological dis-
ease triggering: antibody affinity [50, 51], antigen density
[52], membrane cholesterol content [53], sub-neuronal
location of antigen [53], lipid environment [28], cer-
amide length [54], among others. The appearance of di-
verse antibody populations (as was also verified from the
varied co-occurrences of IgG populations against the dif-
ferent self glycans) would constitute a random process
[2] that, confluencing with the aforementioned factors
could decide which nerve (or cell) will be targeted by an
anti-self glycan autoimmune response. All this would be
reflected as a lack of differences in IgG/IgM discordance
rate between diseases. Overall, the presence of IgG/IgM
discordance could represent a more general autoimmune
phenomenon that merits further investigation.
Even though the “binding site drift” hypothesis was
conceived to explain the origin of anti-GM1 antibodies
in health and disease [2], it can be extended to other
antibodies against self glycans. This hypothesis proposes
that B-lymphocytes reactive to self-glycans originate
from naturally-occurring B-lymphocytes recognizing
structurally-related non-self glycans. In the B-cells reper-
toire involved in the immune response to non-self gly-
cans, some cells (so called “treacherous”) can mutate its
binding site in a way that now it can be activated by an
endogenous or exogenous self glycan (Fig. 4). This
process of specificity change in the B-cells was called
“drift” because it would occur at random and, at least for
anti-GM1 antibodies, it can follow different ways ending
in antibodies having different fine specificities. If the
“starting” B-cell undergoing “drift” is an IgM-producing
cell, the resulting “drifted” B-cell can be stimulated to
produce IgM antibodies or (if class switch is induced) an
IgM/IgG response. Alternatively, as shown in Fig. 4, if
the “drift” process acts on an already switched B-cell, the
immune response will include only IgG-antibodies.
The discordance is less frequent in antibodies recog-
nizing GM2, GM1 or GD1b (“self-glycan A”). This fact
could be related to the presence in normal sera of IgM-
antibodies recognizing these glycolipids [7]. Although
Fig. 4 A hypothesis on the origin of antibodies against self glycans
in patients with neurological disorders. Within the B cell repertoire
able to respond against non-self glycans exist cell populations that
recognize glycan molecules structurally related to self glycans.
Although these so-called “treacherous” B cells cannot be stimulated
by self glycans, during their activation by non-self structures they
can undergo mutations that reshape the binding site, with some
changes now leading to self glycans recognition (drift). These
“drifted” B cells can then be activated by self glycans inducing the
production of IgM antibodies (and IgG ones, if isotype switch
occurs). Thus, these actions lead to a concordant anti-self glycan
IgG/IgM antibody response. Alternatively, non-self glycan-stimulated
“treacherous” B cell can switch their isotype to become “treacherous
switched” B cells, producing anti-non-self glycan IgG antibodies.
Subsequent drift events can now generate “drifted and switched” B
cells that produce IgG after stimulation with self glycans. These latter
steps can generate a discordant anti-self glycan IgG antibody
response (i.e. without IgM antibodies)
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they are low affinity antibodies that have no glycolipid-
mediated biological activity [55], their occurrence is an
indication for the normal presence of IgM-secreting B-
cells that are candidate to be considered “treacherous”
[2]. Autoimmunity triggering could arise from somatic
mutations modifying the binding site of “treacherous” B
cells and allowing high-affinity interaction with self gly-
cans, resembling mechanisms observed for some carbo-
hydrate-binding proteins (e.g. binding site point
mutations leading to increased affinity of an anti-GA1
antibody Fab fragment [56] and an anti-blood group A
[57]). This could allow a more frequent emergence of
anti-self glycan, IgM-producing drifted B cells. From
there on, some activated B cells could likely undergo iso-
type switching to contribute anti-“self glycan A” IgG
antibodies. On the other hand, the large discordance in-
cidence for the other self-glycan-carrying glycolipid anti-
gens that do not have a naturally occurring IgM
counterpart (“self glycan B”) implies that the “drift”
process would occur more frequently at the IgG positive
B-cells. In this case, potential binding site point muta-
tions could modify antibody specificity along with affin-
ity (reminiscing events like the generation of blood
group B enzyme [58] or altered specificity of a lectin
[59]), an expected result considering that somatic hyper-
mutations levels of IgG are significantly higher than
those of IgM [60].
Conclusion
After exploring a large cohort of patients with different
neurological diseases, our work revealed that antibodies of
the IgG isotype against self glycans arose frequently with-
out their corresponding IgM counterpart. In contrast, IgG
antibodies against non-self glycans always exhibited their
corresponding IgM. Interestingly, within the anti-self gly-
can IgG-antibody populations we found antigen-related,
dual trend responses in this IgG/IgM discordance inci-
dence (a low discordance frequency represented by GM2/
GM1/GD1b, and a high discordance frequency encom-
passing GM3/GD3/GD1a/GT1b/GQ1b). Overall, these al-
ternatives in IgG/IgM discordance behavior could result
from B cells undergoing different paths during anti-glycan
immune responses.
Additional files
Additional file 1: Contingency tables for statistical analysis of the
different comparisons. Tables were exported from the analyses
performed in Graph Pad Prism 6. (XLS 59 kb)
Additional file 2: Figure S1. Co-occurrence in IgG antibody reactivity
against different self glycans. Heatmap illustrating reactivity patterns for
patient samples clearly positive for IgG antibodies against at least one
self-glycan antigen. Columns denote each of the self-glycan antibodies,
while rows represent the different patient samples. Positive reactivities
are indicated in red; reactivity absence in gray. (TIF 3103 kb)
Additional file 3: Figure S2. Absence of anti-glycan IgM reactivity in
IgG-reactive sera is not due to IgG interference. Randomly selected
discordant serum samples were subjected to whole IgG fraction removal
using protein G-affinity columns. Briefly, serum pH was adjusted by
adding 1/10 volume of 1 M Tris buffer (pH 8). After filtration, the serum
was passed through Sephadex columns with covalently bound Protein G
(1 ml Protein G / 1 ml serum), with subsequent washes using 100 mM Tris
buffer (pH 8.0). Examples for whole serum samples (“Before Protein G”)
and non-adsorbed fractions (“After Protein G”) assayed for IgM and IgG
using HPTLC-I are shown. (TIF 3814 kb)
Abbreviations
“A” blood group glycolipid: GalNAcα1-(Fucα1,2)3Galβ1-4GlcNAcβ1-3Galβ1-
4Glcβ1-Cer; BSA-PBSt: 1% bovine serum albumin in PBSt;









Performance Thin Layer Chromatography; Nt7: GlcNAcβ1-3Galβ1-3GalNAcα1-
4GalNAcβ1-4GlcNAcβ1-3Manβ1-4Glcβ1-Cer; PBSt: phosphate buffered saline




RDL, FJI and GAN conceived and designed the experiments; RDL acquired
the data; RDL and GAN analyzed and interpreted the data; RDL and GAN
drafted the manuscript; FJI revised its intellectual content; RDL, FJI and GAN
approved the final version of the manuscript.
Authors’ information
RDL, FJI and GAN are Career Investigators of CONICET.
Funding
This work was supported by grants from Secretaría de Ciencia y Tecnología,
UNC (PIP 20180101251); Ministerio de Ciencia y Tecnología, Provincia de
Córdoba (Res 144/18, 2018–19); CONICET (PIP 11220150100226, 2016–18);
and Agencia Nacional de Promoción Científica y Tecnológica - Fondo para la
Investigación Científica y Tecnológica (PICT-0223-2017).
Availability of data and materials
Data and materials are available from the corresponding author on
reasonable request.
Ethics approval and consent to participate
All procedures, performed in accordance with Ethical Guidelines on Research
Involving Human Subjects [17] and with ethical standards as laid down in
the 1964 Declaration of Helsinki and its later amendments, were approved
by the Ethics Committee of CIQUIBIC-CONICET; informed consent was




The authors declare that they have no competing interests.
Received: 11 June 2019 Accepted: 29 August 2019
References
1. Schnaar RL, Suzuki A, Stanley P. Glycosphingolipids. 2nd. Cold Spring
Harbor: Cold Spring Harbor Laboratory Press; 2009. http://www.ncbi.nlm.nih.
gov/pubmed/20301240. Accessed 28 Feb 2018.
Lardone et al. Journal of Biomedical Science           (2019) 26:67 Page 8 of 10
2. Nores GA, Lardone RD, Comín R, Alaniz ME, Moyano AL, Irazoqui FJ.
Anti-GM1 antibodies as a model of the immune response to
self-glycans. Biochim Biophys Acta - Gen Subj. 2008;1780:538–45.
https://doi.org/10.1016/j.bbagen.2007.09.008.
3. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, et al.
Anti-carbohydrate antibodies of normal sera: findings, surprises and
challenges. Mol Immunol. 2009;46:3037–49. https://doi.org/10.1016/j.
molimm.2009.06.010.
4. McVey J, Baker D, Parti R, Berg R, Gudino M, Teschner W. Anti-a and
anti-B titers in donor plasma, plasma pools, and immunoglobulin final
products. Transfusion. 2015;55:S98–104. https://doi.org/10.1111/trf.13114.
5. Springer GF. Blood-Group and Forssman Antigenic Determinants Shared
between Microbes and Mammalian Cells (Part 1 of 3). In: Progress in Allergy,
vol. 15. Basel: KARGER; 1971. p. 9–29. https://doi.org/10.1159/000313046.
6. Alaniz ME, Lardone RD, Yudowski SL, Farace MI, Nores GA. Normally
occurring human anti-GM1 immunoglobulin M antibodies and the immune
response to Bacteria. Infect Immun. 2004;72:2148–51. https://doi.org/10.
1128/IAI.72.4.2148-2151.2004.
7. Mizutamari RK, Wiegandt H, Nores GA. Characterization of anti-ganglioside
antibodies present in normal human plasma. J Neuroimmunol. 1994;50:215–
20. https://doi.org/10.1016/0165-5728(94)90048-5.
8. Gleeson PA. Glycoconjugates in autoimmunity. Biochim Biophys
Acta - Gene Struct Expr. 1994;1197:237–55. https://doi.org/10.1016/0167-
4781(94)00008-Q.
9. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies.
Brain. 2002;125:2591–625. https://doi.org/10.1093/brain/awf272.
10. Kaida K. Antibodies to glycoconjugates in autoimmune neuropathies. Clin
Exp Neuroimmunol. 2015;6:387–94. https://doi.org/10.1111/cen3.12267.
11. Yuki N. Molecular mimicry between gangliosides and
lipopolysaccharides of campylobacter jejuni isolated from patients with
Guillain-Barré syndrome and miller fisher syndrome. J Infect Dis. 1997;
176:S150–3. https://doi.org/10.1086/513800.
12. Yuki N. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome
has a GM1 ganglioside-like structure. J Exp Med. 1993;178:1771–5. https://
doi.org/10.1084/jem.178.5.1771.
13. Nachamkin I, Ung H, Moran AP, Yoo D, Prendergast MM, Nicholson MA,
et al. Ganglioside GM1 mimicry in campylobacter strains from sporadic
infections in the United States. J Infect Dis. 1999;179:1183–9. https://doi.
org/10.1086/314725.
14. Allos BM. Association between campylobacter infection and Guillain-Barré
syndrome. J Infect Dis. 1997;176:S125–8. https://doi.org/10.1086/513783.
15. Willison HJ, Jacobs BC, Van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;
388:717–27. https://doi.org/10.1016/S0140-6736(16)00339-1.
16. Lopez PHH, Lardone RD, Irazoqui FJ, Maccioni M, Nores GA. The origin of
anti-GM1 antibodies in neuropathies: the “binding site drift” hypothesis.
Neurochem Res. 2002;27:687–95. https://doi.org/10.1023/A:1020232318647.
17. Ministry of Health of Argentina. Ethical Guidelines on Research Involving
Human Subjects. Guía para Investigaciones con Seres Humanos. 2011.
http://servicios.infoleg.gob.ar/infolegInternet/anexos/185000-189999/1872
06/texact.htm. Accessed 21 Mar 2018.
18. Dennis RD, Geyer R, Egge H, Menges H, Stirm S, Wiegandt H.
Glycosphingolipids in insects: chemical structures of ceramide
monosaccharide, disaccharide, and trisaccharide from pupae of Calliphora
vicina (Insecta: Diptera). Eur J Biochem. 1985;146:51–8. https://doi.org/10.
1111/j.1432-1033.1985.tb08618.x.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 1957;226:497–509.
http://www.ncbi.nlm.nih.gov/pubmed/13428781. Accessed 28 Feb 2019.
20. Yu RK, Ledeen RW. Gangliosides of human, bovine, and rabbit plasma. J
Lipid Res 1972;13:680–686. http://www.ncbi.nlm.nih.gov/pubmed/5075512.
Accessed 24 Nov 2018.
21. Watanabe K, Arao Y. A new solvent system for the separation of neutral
glycosphingolipids. J Lipid Res. 1981;22:1020–4 http://www.ncbi.nlm.nih.
gov/pubmed/6268725.
22. Cumar FA, Barra HS, Maccioni HJ, Caputto R. Sulfation of
Glycosphingolipids and Related Carbohydrates by Brain Preparations
from Young Rats. J Biol Chem. 1968;243:3807–16 http://www.jbc.org/
content/243/14/3807.
23. Winer MA, Terryberry JW. Glycolipid (excluding ganglioside) autoantibodies.
In: Autoantibodies: Elsevier Science B.V; 2007. p. 314–24. https://doi.org/10.
1016/b978-044482383-0/50046-7.
24. Conrad K, Schneider H, Ziemssen T, Talaska T, Reinhold D, Humbel R-L, et al.
A new line immunoassay for the multiparametric detection of
antiganglioside autoantibodies in patients with autoimmune peripheral
neuropathies. Ann N Y Acad Sci. 2007;1109:256–64. https://doi.org/10.1196/
annals.1398.031.
25. Nores GA, Mizutamari RK, Kremer DM. Chromatographic tank designed to
obtain highly reproducible high-performance thin-layer chromatograms of
gangliosides and neutral glycosphingolipids. J Chromatogr A.
1994;686:155–7. https://doi.org/10.1016/S0021-9673(94)89015-3.
26. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, et
al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol.
1988;23:440–7. https://doi.org/10.1002/ana.410230503.
27. Adams D, Kuntzer T, Burger D, Chofflon M, Magistris MRR, Regli F, et al.
Predictive value of anti-GM1 ganglioside antibodies in neuromuscular
diseases: a study of 180 sera. J Neuroimmunol. 1991;32:223–30. https://doi.
org/10.1016/0165-5728(91)90192-A.
28. Li F, Pestronk A. Autoantibodies to GM1 ganglioside: different reactivity to
GM1-liposomes in amyotrophic lateral sclerosis and lower motor neuron
disorders. J Neurol Sci. 1991;104:209–14. https://doi.org/10.1016/0022-
510X(91)90312-U.
29. Nobile-Orazio E, Carpo M, Meucci N, Grassi MP, Capitani E, Sciacco M, et al.
Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J
Neurol Sci. 1992;109:200–6. https://doi.org/10.1016/0022-510X(92)90169-L.
30. Carpo M, Pedotti R, Allaria S, Lolli F, Matà S, Cavaletti G, et al. Clinical
presentation and outcome of Guillain-Barre and related syndromes in
relation to anti-ganglioside antibodies. J Neurol Sci. 1999;168:78–84. https://
doi.org/10.1016/S0022-510X(99)00173-2.
31. Press R, Matá S, Lolli F, Zhu J, Andersson T, Link H. Temporal profile of
anti-ganglioside antibodies and their relation to clinical parameters and
treatment in Guillain-Barré syndrome. J Neurol Sci. 2001;190:41–7. https://
doi.org/10.1016/S0022-510X(01)00580-9.
32. Tiberti C, Dotta F, Anastasi E, Torresi P, Multari G, Vecci E, et al. Anti-
ganglioside antibodies in new onset type 1 diabetic patients and high risk
subjects. Autoimmunity. 1995;22:43–8.
33. Aoyama K, Ishikura H, Mishima S, Murai M, Tsumura H, Kumakura S, et al.
Guillain-Barré syndrome complicated with hemolytic anemia in association
with antiganglioside GM3 antibody. Am J Med. 2001;110:399–400.
34. Klehmet J, Märschenz S, Ruprecht K, Wunderlich B, Büttner T, Hiemann R, et al.
Analysis of anti-ganglioside antibodies by a line immunoassay in patients with
chronic-inflammatory demyelinating polyneuropathies (CIDP). Clin Chem Lab
Med. 2018;56:919–26. https://doi.org/10.1515/cclm-2017-0792.
35. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: From
structure to effector functions. Front Immunol. 2014;5 OCT:520. https://doi.
org/10.3389/fimmu.2014.00520.
36. Chan CE, Gotze S, Seah GT, Seeberger PH, Tukvadze N, Wenk MR, et al. The
diagnostic targeting of a carbohydrate virulence factor from M.Tuberculosis.
Sci Rep. 2015;5:10281. https://doi.org/10.1038/srep10281.
37. Horiya S, MacPherson IS, Krauss IJ. Recent strategies targeting HIV glycans in vaccine
design. Nat Chem Biol. 2014;10:990–9. https://doi.org/10.1038/nchembio.1685.
38. Daniotti JL, Lardone RD, Vilcaes AA. Dysregulated Expression of Glycolipids
in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to
Promising Targets for Developing Therapeutic Agents. Front Oncol. 2016;5
January:1–11. https://doi.org/10.3389/fonc.2015.00300.
39. Khasbiullina NR, Shilova NV, Navakouski ME, Nokel AY, Knirel YA, Blixt O, et
al. Repertoire of abs primed by bacteria in gnotobiotic mice. Innate Immun.
2018;24:180–7. https://doi.org/10.1177/1753425918763524.
40. Parker W, Lundberg-Swanson K, Holzknecht ZE, Lateef J, Washburn SA,
Braedehoeft SJ, et al. Isohemagglutinins and xenoreactive antibodies:
members of a distinct family of natural antibodies. Hum Immunol. 1996;45:
94–104. https://doi.org/10.1016/0198-8859(95)00216-2.
41. Massó F, Paéz A, Arista A, Salmón L, Montaño L. Antibody response of
Mexican infants to Haemophilus influenzae type b capsular polyribosylribitol
phosphate. Differences between natural and vaccine induced
(oligosaccharide-CRM197 conjugated vaccine) immunization. Arch Med Res.
1996;27:539–45 https://www.scopus.com/record/display.uri?eid=2-s2.0-002
9848973&origin=inward&txGid=c277994ca925b0696a503af54976b174.
42. Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in
autoimmune neuropathies. Trends Immunol. 2013;34:453–9. https://doi.org/10.
1016/j.it.2013.05.001.
43. van den Berg LH, Marrink J, de Jager AE, de Jong HJ, van Imhoff GW, Latov
N, et al. Anti-GM1 antibodies in patients with Guillain-Barré syndrome. J
Lardone et al. Journal of Biomedical Science           (2019) 26:67 Page 9 of 10
Neurol Neurosurg Psychiatry 1992;55:8–11. http://www.ncbi.nlm.nih.gov/
pubmed/1548508. Accessed 24 Nov 2018.
44. Wolfe GI, El-Feky WH, Katz JS, Bryan WW, Wians FH, Barohn RJ. Antibody
panels in idiopathic polyneuropathy and motor neuron disease. Muscle
Nerve. 1997;20:1275–83. https://doi.org/10.1002/(SICI)1097-4598(199710)20:
10<1275::AID-MUS10>3.0.CO;2-2.
45. Caudie C, Vial C, Bancel J, Petiot P, Antoine JC, Gonnaud PM.
Antiganglioside autoantibody profiles in Guillain-Barre syndrome. Ann Biol
Clin (Paris) 2002;60:589–597. http://www.ncbi.nlm.nih.gov/pubmed/1236
8145. Accessed 19 Jul 2018.
46. Fan C, Jin H, Hao H, Gao F, Sun Y, Lu Y, et al. Anti-ganglioside antibodies in
Guillain-Barré syndrome and chronic inflammatory demyelinating
polyneuropathy in Chinese patients. Muscle Nerve. 2017;55:470–5. https://
doi.org/10.1002/mus.25266.
47. Lopez PHH, Lardone RD, Irazoqui FJ, Villa AM, Di Egidio M, Saizar RD, et al.
Variable patterns of anti-GM1 IgM-antibody populations defined by affinity
and fine specificity in patients with motor syndromes: evidence for their
random origin. J Neuroimmunol. 2001;119:131–6. https://doi.org/10.1016/
S0165-5728(01)00355-1.
48. Lardone RD, Yuki N, Odaka M, Daniotti JL, Irazoqui FJ, Nores GA. Anti-GM1
IgG antibodies in Guillain-Barré syndrome: fine specificity is associated with
disease severity. J Neurol Neurosurg Psychiatry. 2010;81:629–33. https://doi.
org/10.1136/jnnp.2009.183665.
49. Lardone RD, Yuki N, Irazoqui FJ, Nores GA, Lardone Ricardo D, Yuki N, et al.
Individual restriction of fine specificity variability in anti-GM1 IgG antibodies
associated with Guillain-Barré syndrome. Sci Rep. 2016;6:19901. https://doi.
org/10.1038/srep19901.
50. Lardone RD, Alaniz ME, Irazoqui FJ, Nores GA. Unusual presence of anti-GM1
IgG-antibodies in a healthy individual, and their possible involvement in the
origin of disease-associated anti-GM1 antibodies. J Neuroimmunol. 2006;
173:174–9. https://doi.org/10.1016/j.jneuroim.2005.11.017.
51. Lopez PHH, Villa AM, Sica REP, Nores GA. High affinity as a disease
determinant factor in anti-GM1 antibodies: comparative characterization of
experimentally induced vs. disease-associated antibodies. J Neuroimmunol.
2002;128:69–76. https://doi.org/10.1016/S0165-5728(02)00139-X.
52. Kremer DM, López PHH, Mizutamari RK, Kremer LJ, Bacile EA, Nores GA.
Factors defining target specificity in antibody-mediated neuropathy:
density-dependent binding of anti-GD (1a) polyclonal IgG from a
neurological patient. J Neurosci Res. 1997;47:636–41. https://doi.org/10.
1002/(SICI)1097-4547(19970315)47:6<636::AID-JNR9>3.0.CO;2-E.
53. Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J, et al.
Anti-ganglioside antibody internalization attenuates motor nerve terminal
injury in a mouse model of acute motor axonal neuropathy. J Clin Invest.
2012;122:1037–51. https://doi.org/10.1172/JCI59110.
54. Ogawa-Goto K, Funamoto N, Abe T, Nagashima K. Different ceramide
compositions of gangliosides between human motor and sensory
nerves. J Neurochem. 1990;55:1486–93. https://doi.org/10.1111/j.1471-
4159.1990.tb04930.x.
55. Mizutamari RK, Kremer LJ, Basile EA, Nores GA. Anti-GM1 ganglioside IgM-
antibodies present in human plasma: affinity and biological activity changes
in a patient with neuropathy. J Neurosci Res. 1998;51:237–42. https://doi.
org/10.1002/(SICI)1097-4547(19980115)51:2<237::AID-JNR12>3.0.CO;2-5.
56. Qiu JX, Kai M, Padlan EA, Marcus DM. Structure-function studies of an anti-
asialo GM1 antibody obtained from a phage display library. J
Neuroimmunol. 1999;97:172–81. https://doi.org/10.1016/S0165-
5728(99)00056-9.
57. Thomas R, Patenaude SI, MacKenzie CR, To R, Hirama T, Young NM, et al.
Structure of an anti-blood group a Fv and improvement of its binding
affinity without loss of specificity. J Biol Chem. 2002;277:2059–64. https://doi.
org/10.1074/jbc.M104364200.
58. Yamamoto FI, Hakomori SI. Sugar-nucleotide donor specificity of histo-
blood group a and B transferases is based on amino acid substitutions. J
Biol Chem 1990;265:19257–19262. http://www.ncbi.nlm.nih.gov/
pubmed/2121736. Accessed 29 Mar 2019.
59. Iobst ST, Drickamer K. Binding of sugar ligands to Ca2+−dependent animal
lectins: II. Generation of high-affinity galactose binding by site-directed
mutagenesis. J Biol Chem 1994;269:15512–15519. http://www.jbc.org/
content/269/22/15512.full.pdf. Accessed 25 Jul 2019.
60. Kitaura K, Yamashita H, Ayabe H, Shini T, Matsutani T, Suzuki R. Different
somatic Hypermutation levels among antibody subclasses disclosed by a
new next-generation sequencing-based antibody repertoire analysis. Front
Immunol. 2017;8:389. https://doi.org/10.3389/fimmu.2017.00389.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lardone et al. Journal of Biomedical Science           (2019) 26:67 Page 10 of 10
